Chelsea and Westminster Hospital
NHS Foundation Trust

Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Group
Summary Notes

Monday 13th December 2021 08.00 to 09.00
(Held via Teams)

2. Minutes and Summary Notes from last meeting

On account of the Trust response to the Covid-19 Pandemic, this meeting was held via Teams.
The minutes and summary notes of the Medicines Group Meeting held on 12th July 2021 were approved. The summary notes will be disseminated and published on the Trust intranet. A quarterly summary report will be drafted and forwarded to the Trust Patient Safety Group meeting for inclusion on the agenda in due course.

3. Matters Arising

The Group noted the matters arising from the previous meeting.

4. Business to be transacted by the Medicines Group

a) Formulary Applications

Full Applications

- **Casirivimab and Imdevimab Solution for Injection (Ronapreve®)**

Requested by Microbiology for the treatment of Covid-19 patients with confirmed SARA-CoV-2 infection, but without a suitable antibody response in line with CMO advice.

On 4th November NHS access to the combination monoclonal antibody casirivimab plus imdevimab (marketed as Ronapreve®) was extended in patients aged 12 and above and should now be considered at a total dose of 2.4g in COVID positive antibody seronegative patients who have been hospitalised specifically to manage the symptoms of COVID infection; and at a total dose of 1.2g in patients who are admitted to hospital for another (Non COVID-related) indication but nonetheless test positive during their hospital stay and are either at high risk of disease progression or COVID infection is considered to be likely to destabilise their existing medical condition or compromise recovery from their hospital procedure. The extension of access to patients with hospital-onset infection will enable a further evaluation of clinical adoption in this cohort.
Outcome: Approved for addition to the formulary

- **Molnupiravir 200mg Capsule (Lagevrio®)**

Requested by Microbiology for the treatment of mild to moderate Covid-19 in adults with a positive SARA-CoV-2 diagnostic test and who have at least one risk factor for developing severe illness in line with CMO Guidance.
Outcome: Approved for addition to the formulary

- **Sotrovimab solution for injection or infusion (Xevudy®)**

Requested by Microbiology for the treatment of COVID-19 patients with confirmed SARS-CoV-2 infection in line with CMO advice.
Outcome: Approved for addition to the formulary

- **Dienogest 2mg Tablet (Zalkya®)**

The presenter was unable to attend on the meeting on the day. This has been deferred to the next meeting.

Ex-panel

- **Human Papilloma Virus Vaccine (Gardasil 9®)**

Requested by GUM, in line with Public Health England guidance to transition from Gardasil quadrivalent to Gardasil-9 as part of the national HPV vaccination programme.
Outcome: Approved for addition to the formulary

Removals

- **Nil**

NICE Approved drug applications

- **TA723 - Bimekizumab for treating moderate to severe plaque psoriasis**

Published by NICE on 01/09/2021
Approved by Chair's action on 14/11/2021
For noting
Outcome: Approved for addition to the formulary for use in line with NICE TA723

Pharmacoeconomic Board requests

- Nil

4.2 Trust Medicines Policy

- **TMP Update - Progress report - December 2021**

TMP Update - Progress report for December 2021
Outcome: Approved

- **TMP - Section 12 - Disposal and destruction of medicines**

Routine review and update
- Update to document titles

Outcome: Approved

- **TMP - Section: 33 - Pharmacy Service outside normal working hours**

Routine review and update
- Inclusion of the location of the Pharmacy electronic medicines cabinet (CWH Site).

Outcome: Approved

- **TMP - Section 34 - Supply and administration of medicines by Non-registered Healthcare Practitioners**

Routine review and update
- Minor formatting changes
- Use of generic terms to improve conciseness of policy
- Addition of responsibilities of TMG Secretary
- Addition of non-registered healthcare staff administering Covid-19 vaccine under National Protocol.

Outcome: Approved

- **TMP - Section 35 - Individual Funding Request Policy**

Routine review and update:
- Updated to incorporate the updated process for online submission of NHSE IFRs via the online Apollo Portal
- Update of references
- Clarification of approval process
- Update to Pharmacoeconomic Board members

Outcome: Approved

4.3 Medicines Optimisation

- **Andexanet alfa for reversal of apixaban or rivaroxaban in patients requiring treatment for life-threatening or uncontrolled gastrointestinal haemorrhage**

New guideline drafted by Haemotology which outlines the storage, reconstitution and use of andexanet alfa (Ondexxya) for the urgent reversal of the factor Xa (FXa) inhibitor anticoagulants, apixaban (Eliquis) and rivaroxaban (Xarelto). It also features a flowchart summarising the reversal of apixaban and rivaroxaban, demonstrating where andexanet alfa fits in the anticoagulation reversal management pathway.
Outcome: Approved

4.4 NICE Technical Appraisals and Guidance

a) NICE Technical Appraisals

2 appraisals published in October 2021
6 appraisals published in November 2021

TA740 - Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer
Formulary status / Action
Currently NOT included on the CWFT formulary
Numbers likely to treat at CWH site: 1-2 patients per year
Numbers likely to treat at WMUH site: 0 patient per year
Date published: 28th Oct
Action: Add to the formulary following receipt of an application form from Oncology Team by 28/01/2022

TA741 - Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer
Formulary status / Action
Currently NOT included on the CWFT formulary
Numbers likely to treat at CWH site: 2-3 patients per year
Numbers likely to treat at WMUH site: 0 patient per year
Date published: 28th Oct
Action: Add to the formulary following receipt of an application form from Oncology Team by 28/01/2022

TA742 - Selpercatinib for treating advanced Thyroid cancer with RET alterations
Formulary status / Action - nil
Currently NOT included on the CWFT formulary
Action: Nil - CWFT NOT Commissioned

TA743 - Crizanlizumab for preventing sickle cell crises in sickle cell disease
Formulary status / Action
Currently NOT included on the CWFT formulary
Action: Confirm commissioning status for CWFT

TA744 - Upadacitinib for treating moderate rheumatoid arthritis
Formulary status / Action
Formulary status / Action
Included on the CWFT formulary
Numbers likely to treat at CWH site: 5-10 patients per year
Numbers likely to treat at WMUH site: 40 patients per year
Action: Update formulary status accordingly to indicate now used in line with NICE TA744

TA745 - NBTXR-3 for treating advanced soft tissue sarcoma (Terminated appraisal)
Formulary status / Action
Action: Nil - Terminated appraisal

TA746 - Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer
Formulary status / Action
Currently included on the CWFT formulary
Action: Confirm commissioning status for CWFT
TA747 - Nintedanib for treating progressive fibrosing interstitial lung diseases
Formulary status / Action
Currently included on the CWFT formulary
Action: Confirm commissioning status for CWFT

a) NICE Highly Specialised Technologies published since last meeting

HST16 - Givosiran for treating acute hepatic porphyria
Formulary status / Action
Currently not included on the CWFT formulary
Action: Nil - CWFT NOT Commissioned

4.5 IVIG requests

- **IVIG Issues for October 2021 - CW Site**

There were 12 IVIG issues in October 2021, with 7 new requests:
Outcome: Noted

- **IVIG Issues for October 2021 - WMUH Site**

There were 12 IVIG issues in October 2021, with 6 new requests:
Outcome: Noted

- **Guidance on switching immunoglobulin (IG) products for existing patients on long term treatment (For noting)**
  - Guidance on switching Immunoglobulin products for existing patient on long term treatment
  - Patient Information Leaflet relating to switching Immunoglobulin products for existing patient on long term treatment

Outcome: Noted

4.6 Items for noting

- **Quarterly Controlled Drug Summary Report - Q2 2021/22**

Quarterly Controlled Drug Summary Report for Q2 2021/22
Outcome: Noted

- **Quarterly Controlled Drugs Accountable Officer Report - Q2 2021/22**

Quarterly CD Accountable Officer Report for Q2 2021/22
Outcome: Noted

- **Patient Group Directions Log - December 2021**

Patient Group Direction Log as of December 2021
  - 99 PGD in use across the Trust
  - 15 PGDs approved to date in 2021 (1 new PGD in Maternity)
  - 1 PGD due to expire in 2021

Outcome: Noted

- **Medication Safety Bulletin - Timely administration of medicines**

Medication Safety Bulletin relating to timely administration of medicines.
Outcome: Noted

- **Trust Medicines Group for Patient Safety Group - November 2021**

Trust Medicines Group report for the Patient Safety Group noted in November 2021
Outcome: Noted

- **MHRA Drug Safety Update - November 2021**

MHRA update for November 2021
Outcome: Noted

4.7 Meeting minutes for noting

- **NWLIF NDP Meeting minutes - 2021**

Minutes from NWLIF NDF meeting held October 2021 with accompanying

- Updated Red List for NWL
- Updated formulary changes

Outcome: Noted

- **Medication Safety Group - October 2021**

Minutes from Medication Safety Group meeting held October 2021
Outcome: Noted

5. Any other business

- **Nil**

6. Date of next meeting

Next meeting
Date: 31st January 2022 at 8-9am
Time: 8am-9am
Location: via Teams